Merck will report its Q3 2026 results on October 29, with investors focused on whether new drug launches like LIPFENDRA, QLEX, and WINREVAIR can compensate for the expected loss of patent exclusivity for Keytruda in 2028. Last quarter, revenue grew 5.07% to $16.61 billion, driven by newer products despite a slight decline in Keytruda sales. Management raised 2026 sales guidance, but analysts have lowered earnings estimates amid concerns about Keytruda's future. Updates on Merck's pipeline, including Phase 3 trials and collaborations, will be key to assessing its growth prospects beyond Keytruda.
Merck's stock is trading at USD 145.27 on Pluang, down 1.34% as of Oct 25, 2026 22:31 WIB. The company holds a market cap of $358.41 billion, with investors showing full buy interest at this time.
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
